Clinically Relevant Changes in Emotional Expression in Children With ADHD Treated With Lisdexamfetamine Dimesylate

Alain Katic; Lawrence Ginsberg; Rakesh Jain; Ben Adeyi; Bryan Dirks; Thomas Babcock; Brian Scheckner; Cynthia Richards; Robert Lasser; Atilla Turgay; Robert L. Findling

doi:10.1177/1087054710389990

Clinically Relevant Changes in Emotional Expression in Children With ADHD Treated With Lisdexamfetamine Dimesylate

Alain Katic, Lawrence Ginsberg, Rakesh Jain, Ben Adeyi, Bryan Dirks, Thomas Babcock, Brian Scheckner, Cynthia Richards, Robert Lasser, Atilla Turgay, Robert L. Findling

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Objective: To describe clinically relevant effects of lisdexamfetamine dimesylate (LDX) on emotional expression (EE) in children with ADHD. Method: Children with ADHD participated in a 7-week, open-label, LDX dose-optimization study. Expression and Emotion Scale for Children (EESC) change scores were analyzed post hoc using two methods to determine proportion of participants with different categories of clinical response based on (a) clinically significant (movement >2 SD from baseline mean)/reliable change (not due to measurement error) and (b) standard error of measurement (SEM) as a measure of clinically meaningful change. Results: With LDX, no participants showed clinically significant/reliable improvement; 0.7% showed clinically significant/reliable deterioration of EE by reliable change index and movement from baseline mean. One third of participants had improved EE by SEM criteria; 9.2% had categorical worsening. Conclusion: Using clinically meaningful change and clinically significant/reliable change categories derived from the EESC, most participants had no worsening of EE with LDX.

Original language	English (US)
Pages (from-to)	384-397
Number of pages	14
Journal	Journal of Attention Disorders
Volume	16
Issue number	5
DOIs	https://doi.org/10.1177/1087054710389990
State	Published - Jul 2012
Externally published	Yes

Keywords

ADHD
LDX
Lisdexamfetamine dimesylate
emotional lability
stimulant

ASJC Scopus subject areas

Developmental and Educational Psychology
Clinical Psychology

Access to Document

10.1177/1087054710389990

Cite this

@article{8a98849b16a74fd3a8010bc937278593,

title = "Clinically Relevant Changes in Emotional Expression in Children With ADHD Treated With Lisdexamfetamine Dimesylate",

abstract = "Objective: To describe clinically relevant effects of lisdexamfetamine dimesylate (LDX) on emotional expression (EE) in children with ADHD. Method: Children with ADHD participated in a 7-week, open-label, LDX dose-optimization study. Expression and Emotion Scale for Children (EESC) change scores were analyzed post hoc using two methods to determine proportion of participants with different categories of clinical response based on (a) clinically significant (movement >2 SD from baseline mean)/reliable change (not due to measurement error) and (b) standard error of measurement (SEM) as a measure of clinically meaningful change. Results: With LDX, no participants showed clinically significant/reliable improvement; 0.7% showed clinically significant/reliable deterioration of EE by reliable change index and movement from baseline mean. One third of participants had improved EE by SEM criteria; 9.2% had categorical worsening. Conclusion: Using clinically meaningful change and clinically significant/reliable change categories derived from the EESC, most participants had no worsening of EE with LDX.",

keywords = "ADHD, LDX, Lisdexamfetamine dimesylate, emotional lability, stimulant",

author = "Alain Katic and Lawrence Ginsberg and Rakesh Jain and Ben Adeyi and Bryan Dirks and Thomas Babcock and Brian Scheckner and Cynthia Richards and Robert Lasser and Atilla Turgay and Findling, {Robert L.}",

note = "Funding Information: Clinical research was funded by the sponsor, Shire Development Inc. Under the direction of the authors, Margaret McLaughlin, PhD, former employee of Ogilvy CommonHealth Scientific Communications (OCHSC) and Michael Pucci, PhD, employee of OCHSC, provided writing assistance for this publication. Editorial assistance in formatting, proofreading, copy editing, and fact checking was also provided by OCHSC. Ben Adeyi, MS, Bryan Dirks, MD, Brian Scheckner, PharmD, Thomas Babcock, DO, from Shire Development Inc. also reviewed and edited the manuscript for scientific accuracy. Shire Development Inc. provided funding to OCHSC for support in writing and editing this manuscript. Although the sponsor was involved in the design, collection, analysis, interpretation, and fact checking of information, the content of this manuscript, the ultimate interpretation, and the decision to submit it for publication in Journal of Attention Disorders were made by the authors independently.",

year = "2012",

month = jul,

doi = "10.1177/1087054710389990",

language = "English (US)",

volume = "16",

pages = "384--397",

journal = "Journal of Attention Disorders",

issn = "1087-0547",

publisher = "SAGE Publications Inc.",

number = "5",

}

TY - JOUR

T1 - Clinically Relevant Changes in Emotional Expression in Children With ADHD Treated With Lisdexamfetamine Dimesylate

AU - Katic, Alain

AU - Ginsberg, Lawrence

AU - Jain, Rakesh

AU - Adeyi, Ben

AU - Dirks, Bryan

AU - Babcock, Thomas

AU - Scheckner, Brian

AU - Richards, Cynthia

AU - Lasser, Robert

AU - Turgay, Atilla

AU - Findling, Robert L.

N1 - Funding Information: Clinical research was funded by the sponsor, Shire Development Inc. Under the direction of the authors, Margaret McLaughlin, PhD, former employee of Ogilvy CommonHealth Scientific Communications (OCHSC) and Michael Pucci, PhD, employee of OCHSC, provided writing assistance for this publication. Editorial assistance in formatting, proofreading, copy editing, and fact checking was also provided by OCHSC. Ben Adeyi, MS, Bryan Dirks, MD, Brian Scheckner, PharmD, Thomas Babcock, DO, from Shire Development Inc. also reviewed and edited the manuscript for scientific accuracy. Shire Development Inc. provided funding to OCHSC for support in writing and editing this manuscript. Although the sponsor was involved in the design, collection, analysis, interpretation, and fact checking of information, the content of this manuscript, the ultimate interpretation, and the decision to submit it for publication in Journal of Attention Disorders were made by the authors independently.

PY - 2012/7

Y1 - 2012/7

N2 - Objective: To describe clinically relevant effects of lisdexamfetamine dimesylate (LDX) on emotional expression (EE) in children with ADHD. Method: Children with ADHD participated in a 7-week, open-label, LDX dose-optimization study. Expression and Emotion Scale for Children (EESC) change scores were analyzed post hoc using two methods to determine proportion of participants with different categories of clinical response based on (a) clinically significant (movement >2 SD from baseline mean)/reliable change (not due to measurement error) and (b) standard error of measurement (SEM) as a measure of clinically meaningful change. Results: With LDX, no participants showed clinically significant/reliable improvement; 0.7% showed clinically significant/reliable deterioration of EE by reliable change index and movement from baseline mean. One third of participants had improved EE by SEM criteria; 9.2% had categorical worsening. Conclusion: Using clinically meaningful change and clinically significant/reliable change categories derived from the EESC, most participants had no worsening of EE with LDX.

AB - Objective: To describe clinically relevant effects of lisdexamfetamine dimesylate (LDX) on emotional expression (EE) in children with ADHD. Method: Children with ADHD participated in a 7-week, open-label, LDX dose-optimization study. Expression and Emotion Scale for Children (EESC) change scores were analyzed post hoc using two methods to determine proportion of participants with different categories of clinical response based on (a) clinically significant (movement >2 SD from baseline mean)/reliable change (not due to measurement error) and (b) standard error of measurement (SEM) as a measure of clinically meaningful change. Results: With LDX, no participants showed clinically significant/reliable improvement; 0.7% showed clinically significant/reliable deterioration of EE by reliable change index and movement from baseline mean. One third of participants had improved EE by SEM criteria; 9.2% had categorical worsening. Conclusion: Using clinically meaningful change and clinically significant/reliable change categories derived from the EESC, most participants had no worsening of EE with LDX.

KW - ADHD

KW - LDX

KW - Lisdexamfetamine dimesylate

KW - emotional lability

KW - stimulant

UR - http://www.scopus.com/inward/record.url?scp=84864812998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864812998&partnerID=8YFLogxK

U2 - 10.1177/1087054710389990

DO - 10.1177/1087054710389990

M3 - Article

C2 - 21173426

AN - SCOPUS:84864812998

SN - 1087-0547

VL - 16

SP - 384

EP - 397

JO - Journal of Attention Disorders

JF - Journal of Attention Disorders

IS - 5

ER -

Clinically Relevant Changes in Emotional Expression in Children With ADHD Treated With Lisdexamfetamine Dimesylate

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this